cyclosporin
potenti
role
treatment
sar
dear
sir
welcom
jasper
chan
colleagu
review
isol
novel
human
betacoronaviru
two
patient
share
desir
research
group
emerg
viral
pathogen
absenc
evidencebas
treat
coronavirusassoci
sever
acut
respiratori
syndrom
sar
worri
author
list
sever
agent
vitro
activ
sar
coronaviru
refer
literatur
describ
anticoronaviru
activ
cyclophilin
inhibitor
pfefferl
cowork
adopt
system
biolog
approach
identifi
coronavirusehost
interact
use
genomewid
yeasttwo
hybrid
screen
identifi
interact
coronaviru
nonstructur
protein
sever
immunophilin
group
molecul
role
tcell
activ
via
calcineurinnfat
pathway
addit
found
induc
express
thu
implic
cytokin
dysregul
seen
sar
high
serum
level
previous
demonstr
correl
mortal
p
high
apach
ii
score
p
patient
acut
respiratori
distress
syndrom
importantli
pfefferl
et
al
found
cyclophilin
inhibitor
cyclosporin
inhibit
sar
coronaviru
replic
cell
cultur
well
inhibit
induct
de
wild
colleagu
also
report
vitro
anticoronaviru
activ
cyclosporin
addit
cyclosporin
found
suppress
hepat
c
viru
hcv
replic
vitro
prompt
assess
role
hcv
infect
studi
patient
chronic
hcv
infect
inou
et
al
compar
treatment
ifn
cyclosporin
versu
ifn
alon
two
treatment
group
differ
significantli
importantli
display
signific
differ
pretreat
viral
load
viru
genotyp
found
combin
therapi
superior
monotherapi
ifn
result
significantli
improv
virolog
respons
hcv
rna
disappear
treatment
follow
significantli
improv
biochem
respons
alt
normalis
follow
encouragingli
signific
differ
rate
advers
event
treatment
two
group
nonimmunosuppress
cyclosporin
describ
retain
vitro
antihcv
activ
make
attract
candid
clinic
trial
summari
tantalis
vitro
evid
cyclosporin
anticoronaviru
agent
well
potenti
diseasemodifi
role
sar
inhibit
virusmedi
induct
latter
properti
interest
consid
earli
corticosteroid
treatment
initi
combat
pulmonari
inflamm
result
increas
level
viraemia
may
associ
reduc
surviv
sar
furthermor
vitro
antihcv
activ
cyclosporin
translat
clinic
benefit
human
appear
safe
therapi
therefor
advoc
trial
cyclosporin
consid
inevit
event
futur
case
sar
aspergillu
endocard
era
new
antifung
major
role
antigen
detect
steinbach
colleagu
recent
report
journal
clinic
epidemiolog
invas
aspergillosi
use
larg
registri
identifi
herein
describ
case
aspergillu
endocard
ae
except
rare
diseas
ae
repres
less
fungal
endocard
associ
mortal
rate
high
diagnosi
challeng
often
delay
due
nonspecif
clinic
featur
neg
blood
cultur
case
optim
therapeut
manag
remain
poorli
understood
describ
clinic
microbiolog
characterist
outcom
ae
studi
ae
case
enrol
french
nationwid
prospect
mycendo
studi
subsequ
case
declar
french
nation
refer
centr
invas
mycos
antifung
institut
pasteur
pari
diagnosi
definit
ae
consid
accord
previous
publish
modifi
duke
criteria
feasibl
serum
sampl
sequenti
collect
detect
aspergillu
galactomannan
platelia
aspergillu
enzym
immunoassay
biorad
marnelacoquett
franc
bdglucan
fungitel
assay
associ
cape
cod
falmouth
mass
blood
sampl
surgic
cardiac
materi
screen
fungal
dna
fungal
dna
screen
serum
surgic
cardiac
materi
perform
previous
describ
eight
case
observ
januari
may
analyz
tabl
two
previous
publish
part
seven
patient
met
modifi
duke
criteria
definit
ae
last
case
case
n
also
consid
ae
sinc
combin
known
aspergillu
colon
respiratori
tract
valvular
veget
posit
gm
polymeras
chain
reaction
pcr
aspergillu
fumigatu
blood
absenc
microorgan
identifi
blood
favor
outcom
antifung
therapi
six
patient
tabl
immunocompromis
four
underw
solid
organ
transplant
sot
one
prolong
neutropenia
one
receiv
prolong
corticosteroid
therapi
five
immunocompromis
patient
recent
oper
median
month
rang
month
diagnosi
ae
two
latter
patient
risk
factor
ae
recent
cardiac
surgeri
aortic
valv
replac
aortic
stenosi
case
n
repair
congenit
heart
diseas
case
n
patient
leftsid
ae
concomit
rightsid
ae
veget
describ
larg
median
size
mm
rang
annular
abscess
detect
case
case
least
one
embolu
part
clinic
present
blood
cultur
neg
case
note
three
patient
receiv
fluconazol
blood
cultur
perform
cultur
cardiac
surgic
sampl
posit
test
case
detect
bdglucan
bg
posit
test
case
diagnosi
valu
pgml
case
treatment
valu
remain
pgml
test
patient
median
followup
day
rang
despit
favor
evolut
patient
aspergillu
galactomannan
gm
detect
test
patient
preced
posit
cultur
case
none
patient
present
describ
risk
factor
fals
posit
gm
serum
followup
gm
becam
neg
patient
surviv
case
n
pcr
detect
fumigatu
dna
cardiac
surgic
sampl
patient
serum
patient
includ
neg
blood
cultur
six
patient
underw
cardiac
surgeri
part
initi
manag
tabl
surgeri
reject
patient
n
high
risk
procedurerel
mortal
patient
receiv
voriconazol
either
